PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.2088
https://www.valueinhealthjournal.com/article/S1098-3015(22)04293-0/fulltext
Section Title :
Section Order :
11648
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04293-0&doi=10.1016/j.jval.2022.09.2088